Literature DB >> 11788549

IL-10 therapy in Crohn's disease: at the crossroads. Treatment of Crohn's disease with the anti-inflammatory cytokine interleukin 10.

H Herfarth1, J Schölmerich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11788549      PMCID： PMC1773119          DOI： 10.1136/gut.50.2.146

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

1.  Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma.

Authors:  H Tilg; C van Montfrans; A van den Ende; A Kaser; S J H van Deventer; S Schreiber; M Gregor; O Ludwiczek; P Rutgeerts; C Gasche; J C Koningsberger; L Abreu; I Kuhn; M Cohard; A LeBeaut; P Grint; G Weiss
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease.

Authors:  J F Colombel; P Rutgeerts; H Malchow; M Jacyna; O H Nielsen; J Rask-Madsen; S Van Deventer; A Ferguson; P Desreumaux; A Forbes; K Geboes; L Melani; M Cohard
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 3.  Properties and functions of interleukin-10.

Authors:  T R Mosmann
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

4.  Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

Authors:  L Steidler; W Hans; L Schotte; S Neirynck; F Obermeier; W Falk; W Fiers; E Remaut
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

5.  Interleukin 10 gene transfer prevents experimental colitis in rats.

Authors:  G Barbara; Z Xing; C M Hogaboam; J Gauldie; S M Collins
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

Review 6.  Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation.

Authors:  D M Rennick; M M Fort
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-06       Impact factor: 4.052

7.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

Authors:  S Schreiber; R N Fedorak; O H Nielsen; G Wild; C N Williams; S Nikolaus; M Jacyna; B A Lashner; A Gangl; P Rutgeerts; K Isaacs; S J van Deventer; J C Koningsberger; M Cohard; A LeBeaut; S B Hanauer
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

8.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.

Authors:  R N Fedorak; A Gangl; C O Elson; P Rutgeerts; S Schreiber; G Wild; S B Hanauer; A Kilian; M Cohard; A LeBeaut; B Feagan
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

9.  Proinflammatory effects of IL-10 during human endotoxemia.

Authors:  F N Lauw; D Pajkrt; C E Hack; M Kurimoto; S J van Deventer; T van der Poll
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

10.  Subtherapeutic corticosteroids potentiate the ability of interleukin 10 to prevent chronic inflammation in rats.

Authors:  H H Herfarth; U Böcker; R Janardhanam; R B Sartor
Journal:  Gastroenterology       Date:  1998-10       Impact factor: 22.682
  10 in total
  19 in total

Review 1.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Authors:  Madharasi V A Pichai; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 3.  The role of mucosal T lymphocytes in regulating intestinal inflammation.

Authors:  Holm H Uhlig; Fiona Powrie
Journal:  Springer Semin Immunopathol       Date:  2005-06-15

Review 4.  Resolution of Crohn's disease.

Authors:  Heike Schmitt; Clemens Neufert; Markus F Neurath; Raja Atreya
Journal:  Semin Immunopathol       Date:  2019-09-24       Impact factor: 9.623

5.  Heterogeneity of subordination of the IL-18/IFN-γ axis to caspase-1 among patients with Crohn's disease.

Authors:  Anne Jarry; Céline Bossard; Laure Droy-Dupré; Christelle Volteau; Arnaud Bourreille; Guillaume Meurette; Jean-François Mosnier; Christian L Laboisse
Journal:  Lab Invest       Date:  2015-07-13       Impact factor: 5.662

6.  Alterations to chromatin in intestinal macrophages link IL-10 deficiency to inappropriate inflammatory responses.

Authors:  Jeremy M Simon; James P Davis; Saangyoung E Lee; Matthew R Schaner; Gregory R Gipson; Matthew Weiser; R Balfour Sartor; Hans H Herfarth; Reza Rahbar; Timothy S Sadiq; Mark J Koruda; Dermot P McGovern; Jason D Lieb; Karen L Mohlke; Terrence S Furey; Shehzad Z Sheikh
Journal:  Eur J Immunol       Date:  2016-06-01       Impact factor: 5.532

7.  IL-10/HMOX1 signaling modulates cochlear inflammation via negative regulation of MCP-1/CCL2 expression in cochlear fibrocytes.

Authors:  Jeong-Im Woo; Sung-Hee Kil; Sejo Oh; Yoo-Jin Lee; Raekil Park; David J Lim; Sung K Moon
Journal:  J Immunol       Date:  2015-03-16       Impact factor: 5.422

Review 8.  IL-10 and its related cytokines for treatment of inflammatory bowel disease.

Authors:  Ming-Cai Li; Shao-Heng He
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

Review 9.  Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease.

Authors:  Hidetoshi Takedatsu; Keiichi Mitsuyama; Takuji Torimura
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 10.  Why interleukin-10 supplementation does not work in Crohn's disease patients.

Authors:  Gareth J Marlow; Dominique van Gent; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2013-07-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.